UBS Group Analysts Give Merck KGaA (FRA:MRK) a €96.00 Price Target

UBS Group set a €96.00 ($111.63) target price on Merck KGaA (FRA:MRK) in a report published on Thursday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.

Several other research firms have also commented on MRK. HSBC set a €96.00 ($111.63) price target on Merck KGaA and gave the stock a neutral rating in a research report on Thursday, August 15th. Bank of America set a €110.00 ($127.91) target price on Merck KGaA and gave the company a neutral rating in a research report on Friday, September 13th. DZ Bank reaffirmed a buy rating on shares of Merck KGaA in a research report on Wednesday, August 14th. Credit Suisse Group set a €110.00 ($127.91) target price on Merck KGaA and gave the company a buy rating in a research report on Friday, September 6th. Finally, Barclays set a €85.00 ($98.84) target price on Merck KGaA and gave the company a sell rating in a research report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and five have issued a buy rating to the company. Merck KGaA currently has an average rating of Hold and an average target price of €101.88 ($118.47).

Shares of MRK traded up €1.85 ($2.15) during trading hours on Thursday, hitting €108.00 ($125.58). The company had a trading volume of 770,765 shares. Merck KGaA has a one year low of €76.60 ($89.07) and a one year high of €115.00 ($133.72). The company’s fifty day moving average price is €105.44 and its two-hundred day moving average price is €96.92.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Recommended Story: What is meant by holder of record?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit